Master Protocols to Study Multiple Therapies, Multiple

Citation Report

#	Article	IF	Citations
1	Precision medicine in airway diseases: moving to clinical practice. European Respiratory Journal, 2017, 50, 1701655.	3.1	151
3	Clinical Trial Design for Alcoholic Hepatitis. Seminars in Liver Disease, 2017, 37, 332-342.	1.8	18
4	Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research. Journal of Experimental and Clinical Cancer Research, 2017, 36, 128.	3.5	18
5	Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?. Gynecologic Oncology Research and Practice, 2017, 4, 13.	3.6	26
6	Drug evaluation studies in neonates: how to overcome the current limitations. Expert Review of Clinical Pharmacology, 2018, 11, 387-396.	1.3	9
7	The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?. Neuro-Oncology, 2018, 20, 1034-1043.	0.6	100
8	Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment. Journal of Alzheimer's Disease, 2018, 64, S23-S31.	1.2	11
9	Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease. Clinical Pharmacology and Therapeutics, 2018, 104, 282-289.	2.3	12
10	Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology, 2018, 29, 1235-1248.	0.6	196
11	Novel Trial Design in Sepsis. , 2018, , 217-230.		0
12	Editorial: Lessons Learned From a "Failed" Clinical Trial. Arthritis and Rheumatology, 2018, 70, 1364-1365.	2.9	2
13	Platform trials arrive on time for glioblastoma. Neuro-Oncology, 2018, 20, 723-725.	0.6	14
14	Catalyzing the field of precision oncology, one basket at a time. Nature Medicine, 2018, 24, 387-388.	15.2	3
15	Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine. Circulation, 2018, 137, 2551-2553.	1.6	63
16	Handbook of Sepsis. , 2018, , .		10
17	Approvals in 2017: gene therapies and site-agnostic indications. Nature Reviews Clinical Oncology, 2018, 15, 127-128.	12.5	17
18	When biomarkers define a drug indication. Expert Review of Molecular Diagnostics, 2018, 18, 315-317.	1.5	7
19	Advancing the management of obstructive airways diseases through translational research. Clinical and Experimental Allergy, 2018, 48, 493-501.	1.4	0

#	Article	IF	Citations
20	Moving towards a molecular taxonomy of autoimmune rheumatic diseases. Nature Reviews Rheumatology, 2018, 14, 75-93.	3.5	80
21	Child-centred research is the key to progress. Nature Reviews Rheumatology, 2018, 14, 69-70.	3.5	1
22	Master protocols in lung cancer: experience from Lung Master Protocol. Current Opinion in Oncology, 2018, 30, 92-97.	1.1	15
23	Comprehensive analysis of the clinical immuno-oncology landscape. Annals of Oncology, 2018, 29, 84-91.	0.6	422
24	Searching for superstool: maximizing the therapeutic potential of FMT. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 387-388.	8.2	22
25	Trial Design Innovations to Accelerate Therapeutic Advances in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 946-948.	2.2	9
27	Adaptive and platform trials in remote damage control resuscitation. Journal of Trauma and Acute Care Surgery, 2018, 84, S28-S34.	1.1	4
28	Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research. Clinical Infectious Diseases, 2018, 66, 1140-1146.	2.9	17
29	Proton Beam Therapy â€" the Challenges of Delivering High-quality Evidence of Clinical Benefit. Clinical Oncology, 2018, 30, 280-284.	0.6	21
30	Treatable traits of chronic airways disease. Current Opinion in Pulmonary Medicine, 2018, 24, 24-31.	1.2	24
31	Considerations About the Use of Biomarkers in Cancer Clinical Trials. Clinical Pharmacology and Therapeutics, 2018, 103, 25-27.	2.3	2
32	Tumor-Agnostic Drug Development. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 184-187.	1.8	29
33	Do immune checkpoint inhibitors need new studies methodology?. Journal of Thoracic Disease, 2018, 10, S1564-S1580.	0.6	58
34	From scientific discovery to treatments for rare diseases â€" the view from the National Center for Advancing Translational Sciences â€" Office of Rare Diseases Research. Orphanet Journal of Rare Diseases, 2018, 13, 196.	1.2	84
36	Long hidden sepsis subgroup may benefit from immune therapy. Journal of Emergency and Critical Care Medicine, 2018, 2, 106-106.	0.7	0
37	Precision Trial Drawer, a Computational Tool to Assist Planning of Genomics-Driven Trials in Oncology. JCO Precision Oncology, 2018, 2, 1-16.	1.5	2
38	Recommendations for the design of small population clinical trials. Orphanet Journal of Rare Diseases, 2018, 13, 195.	1.2	68
41	The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies. European Journal of Cancer, 2018, 103, 259-266.	1.3	13

#	ARTICLE	IF	CITATIONS
42	Accelerating anticancer drug development â€" opportunities and trade-offs. Nature Reviews Clinical Oncology, 2018, 15, 777-786.	12.5	52
43	Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children. Journal of Clinical Pharmacology, 2018, 58, S58-S72.	1.0	21
44	New clinical trial designs for establishing drug efficacy and safety in a precision medicine era. Diabetes, Obesity and Metabolism, 2018, 20, 14-18.	2.2	19
45	Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study. Annals of Oncology, 2018, 29, 2296-2301.	0.6	13
46	Signature program: a platform of basket trials. Oncotarget, 2018, 9, 21383-21395.	0.8	36
47	Methotrexate Monotherapy for Induction and Maintenance of Clinical Remission in Ulcerative Colitis: Dead on Arrival. Gastroenterology, 2018, 155, 967-969.	0.6	3
48	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. Annals of Oncology, 2018, 29, 2175-2182.	0.6	20
49	Master protocol trials in oncology: Review and new trial designs. Contemporary Clinical Trials Communications, 2018, 12, 1-8.	0.5	81
50	Phase 3 adaptive trial design options in treatment of complicated urinary tract infection. Pharmaceutical Statistics, 2018, 17, 811-822.	0.7	2
51	The First Year of the Food and Drug Administration Oncology Center of Excellence. Cancer Journal (Sudbury, Mass), 2018, 24, 131-135.	1.0	6
52	Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes. Diabetologia, 2018, 61, 1748-1757.	2.9	43
53	Next-generation sequencing in drug development: target identification and genetically stratified clinical trials. Drug Discovery Today, 2018, 23, 1776-1783.	3.2	46
54	The Immune Landscape of Nonâ€"Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 24-38.	2.5	14
55	Reply to Voelkel and Newman: The Light at the End of the Long Pulmonary Hypertension Tunnel Brightens. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 820-821.	2.5	0
57	Primary brain tumours in adults. Lancet, The, 2018, 392, 432-446.	6.3	882
58	Overview on Clinical Relevance of Intra-Tumor Heterogeneity. Frontiers in Medicine, 2018, 5, 85.	1.2	182
59	Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC^{4}E): the ALIC^{4}E protocol. BMJ Open, 2018, 8, e021032.	0.8	20
60	Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. International Journal of Molecular Sciences, 2018, 19, 739.	1.8	44

#	Article	IF	Citations
61	Bioemergency Planning. , 2018, , .		0
62	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. Critical Reviews in Oncology/Hematology, 2018, 130, 13-26.	2.0	34
63	The US Food and Drug Administration's use of pathologic complete response as regulatory endpoint: Did it pay off?. Journal of Cancer Policy, 2018, 16, 49-51.	0.6	1
64	Implementing Optimal Designs for Dose–Response Studies Through Adaptive Randomization for a Small Population Group. AAPS Journal, 2018, 20, 85.	2.2	1
65	Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net. Clinical Infectious Diseases, 2018, 67, 1922-1931.	2.9	23
66	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. Clinical Pharmacology and Therapeutics, 2019, 105, 582-597.	2.3	8
67	Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols. Therapeutic Innovation and Regulatory Science, 2019, 53, 270-278.	0.8	22
69	New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer. Journal of Clinical Medicine, 2019, 8, 1173.	1.0	27
70	Have clinical trials in HIV finally matured?. Lancet HIV,the, 2019, 6, e561-e563.	2.1	2
71	Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations. Journal of Cystic Fibrosis, 2019, 18, 685-692.	0.3	30
72	Reporting of master protocols towards a standardized approach: A systematic review. Contemporary Clinical Trials Communications, 2019, 15, 100406.	0.5	27
73	Precision medicine for acute pancreatitis: current status and future opportunities. Precision Clinical Medicine, 2019, 2, 81-86.	1.3	22
74	Regulatory Considerations for the Use of Biomarkers and Personalized Medicine in CNS Drug Development: A European Perspective. Handbook of Behavioral Neuroscience, 2019, , 259-275.	0.7	1
75	Building a European 'network of networks' for stroke clinical research – The European Stroke Organisation Trials Alliance (ESOTA). European Stroke Journal, 2019, 4, 224-232.	2.7	2
76	A look at clinical trial design for new antimicrobials for the adult population. Expert Review of Clinical Pharmacology, 2019, 12, 1037-1046.	1.3	8
77	Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations. Life Sciences, 2019, 239, 117009.	2.0	142
78	Phage Therapy: A Practical Approach. , 2019, , .		22
79	Light and shadow on innovative clinical trial designs: reflections from the EORTC-PAMM course on 'preclinical and early-phase clinical pharmacology'. Expert Review of Clinical Pharmacology, 2019, 12, 1033-1036.	1.3	4

#	Article	IF	Citations
80	Pharmacokinetic and pharmacodynamic considerations for NMDA-receptor antagonist ketamine in the treatment of chronic neuropathic pain: an update of the most recent literature. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 1033-1041.	1.5	41
81	Adaptive platform trials: definition, design, conduct and reporting considerations. Nature Reviews Drug Discovery, 2019, 18, 797-807.	21.5	218
82	Statistical considerations for rare diseases drug development. Journal of Biopharmaceutical Statistics, 2019, 29, 874-886.	0.4	6
84	Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clinical Trials, 2019, 16, 645-656.	0.7	11
85	Precision Oncology—The Quest for Evidence. Journal of Personalized Medicine, 2019, 9, 43.	1.1	13
86	Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology, 2019, 157, 1032-1043.e1.	0.6	48
87	Utilizing shared internal control arms and historical information in small-sized platform clinical trials. Journal of Biopharmaceutical Statistics, 2019, 29, 845-859.	0.4	8
88	Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials, 2019, 20, 572.	0.7	232
89	Retrospective analysis of treatment patterns among recurrent/metastatic soft tissue sarcoma patients who consulted medical oncologists in Japan. Journal of Orthopaedic Science, 2019, 24, 1081-1087.	0.5	1
90	Pharmacogenomics in Cancer Therapeutics. , 2019, , 123-132.		0
91	Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?. Clinical Cancer Research, 2019, 25, 3210-3219.	3.2	35
92	Challenges with Novel Clinical Trial Designs: Master Protocols. Clinical Cancer Research, 2019, 25, 2049-2057.	3.2	35
93	Multi-part balanced incomplete-block designs. Statistical Papers, 2019, 60, 405-426.	0.7	3
94	Modernizing Clinical Trials for Patients With Cancer. JAMA - Journal of the American Medical Association, 2019, 321, 447.	3.8	15
95	Advancing Drug Development in Gynecologic Malignancies. Clinical Cancer Research, 2019, 25, 4874-4880.	3.2	18
96	Are Global Health Systems Ready for Transformative Therapies?. Value in Health, 2019, 22, 627-641.	0.1	20
97	Testing monotherapy and combination therapy in one trial with biomarker consideration. Contemporary Clinical Trials, 2019, 82, 53-59.	0.8	1
98	An introduction to clinical trial design. Paediatric Respiratory Reviews, 2019, 32, 30-35.	1.2	19

#	ARTICLE	IF	CITATIONS
99	Master protocols in clinical trials: a universal Swiss Army knife?. Lancet Oncology, The, 2019, 20, e336-e342.	5.1	36
100	Mind the gap? The platform trial as a working environment. Trials, 2019, 20, 297.	0.7	28
101	To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. Neuro-Oncology, 2019, 21, 1239-1249.	0.6	16
102	This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. Trials, 2019, 20, 264.	0.7	42
103	Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. Trials, 2019, 20, 294.	0.7	37
104	Clinical trials in end-stage renal disease—priorities and challenges. Nephrology Dialysis Transplantation, 2019, 34, 1084-1089.	0.4	11
106	Depressive disorders: Treatment failures and poor prognosis over the last 50 years. Pharmacology Research and Perspectives, 2019, 7, e00472.	1.1	76
108	Valuing antibiotics: The role of the hospital clinician. International Journal of Antimicrobial Agents, 2019, 54, 16-22.	1.1	1
109	Research Note: Adaptive trials. Journal of Physiotherapy, 2019, 65, 113-116.	0.7	0
110	Commentary on â€œStatistics at FDA: Reflections on the Past Six Yearsâ€. Statistics in Biopharmaceutical Research, 2019, 11, 17-19.	0.6	0
111	Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology. Frontiers in Immunology, 2019, 10, 924.	2.2	31
112	Statistics at FDA: Reflections on the Past Six Years. Statistics in Biopharmaceutical Research, 2019, 11, 1-12.	0.6	9
113	A Network Approach to Developing Immuno-Oncology Combinations in Canada. Current Oncology, 2019, 26, 73-79.	0.9	1
114	Implementing unequal randomization in clinical trials with heterogeneous treatment costs. Statistics in Medicine, 2019, 38, 2905-2927.	0.8	16
115	Trial Refresh: A Case for an Adaptive Platform Trial for Pulmonary Exacerbations of Cystic Fibrosis. Frontiers in Pharmacology, 2019, 10, 301.	1.6	7
116	Past, present and future perspectives in nonalcoholic fatty liver disease. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 377-386.	8.2	357
117	Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program. Pharmaceutical Medicine, 2019, 33, 89-98.	1.0	4
118	Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. European Respiratory Journal, 2019, 53, 1802058.	3.1	177

#	Article	IF	Citations
119	Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precision Oncology, 2019, 3, 1-13.	1.5	46
120	Preoperative bowel stimulation prior to ileostomy closure to restore bowel function more quickly and improve postoperative outcomes: a systematic review. Colorectal Disease, 2019, 21, 994-1003.	0.7	14
121	Perspectives in Neonatal Pharmacology: Drug Discovery, Knowledge Integration and Structured Prioritization. Current Pharmaceutical Design, 2019, 24, 4839-4841.	0.9	4
122	TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. Journal of the National Cancer Institute, 2020, 112, 38-45.	3.0	15
123	PRN OPINION PAPER: Application of precision medicine across pharmacy specialty areas. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 288-302.	0.5	10
125	Precision medicine in multiple myeloma: are we there yet?. Expert Review of Precision Medicine and Drug Development, 2019, 4, 51-53.	0.4	5
126	Current and Future Strategies for Treatment of Relapsed Neuroblastoma. , 2019, , 263-281.		1
127	New clinical trial designs in the era of precision medicine. Molecular Oncology, 2019, 13, 549-557.	2.1	89
128	Recommendations for the design of therapeutic trials for neonatal seizures. Pediatric Research, 2019, 85, 943-954.	1.1	52
129	Limits of traditional evidence-based medicine methodologies exemplified by the novel era in psoriatic arthritis drug development. Expert Review of Clinical Immunology, 2019, 15, 441-444.	1.3	2
130	Moving forward from drug-centred to patient-centred research. European Respiratory Journal, 2019, 53, 1801870.	3.1	14
131	Current state of clinical trials in breast cancer brain metastases. Neuro-Oncology Practice, 2019, 6, 392-401.	1.0	16
132	On the need to adjust for multiplicity in confirmatory clinical trials with master protocols. Annals of Oncology, 2019, 30, 506-509.	0.6	34
133	Challenges and approaches to implementing master/basket trials in oncology. Blood Advances, 2019, 3, 2237-2243.	2.5	11
134	Development of a neonatal adverse event severity scale through a Delphi consensus approach. Archives of Disease in Childhood, 2019, 104, 1167-1173.	1.0	40
135	Bayesian Basket Designs for Cancer Clinical Trials. Japanese Journal of Biometrics, 2019, 39, 103-122.	0.0	0
136	Simultaneous Evaluation of Diagnostic Assays for Pharyngeal and Rectal Neisseria gonorrhoeae and Chlamydia trachomatis Using a Master Protocol. Clinical Infectious Diseases, 2020, 71, 2314-2322.	2.9	15
137	Contributing to Global Health: Development of a Consensus-Based Whole Systems Research Strategy for Anthroposophic Medicine. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-14.	0.5	13

#	ARTICLE	IF	CITATIONS
138	Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations. JCO Precision Oncology, 2019, 3, 1-12.	1.5	36
139	A Collection of Statistical Methods for Precision Oncology. JCO Precision Oncology, 2019, 3, 1-3.	1.5	0
140	Choose to Lead. Journal of the American Statistical Association, 2019, 114, 1427-1435.	1.8	1
141	Introduction by the Guest Editor: Oncologic Precision Medicine and the Use of Basket and Umbrella Clinical Trials. Cancer Journal (Sudbury, Mass), 2019, 25, 243-244.	1.0	0
142	Future Approaches to Precision Oncology–Based Clinical Trials. Cancer Journal (Sudbury, Mass), 2019, 25, 300-304.	1.0	8
143	Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform. Cancer Journal (Sudbury, Mass), 2019, 25, 282-286.	1.0	9
144	Precision Cancer Trials With Immunomodulatory Agents. Cancer Journal (Sudbury, Mass), 2019, 25, 287-295.	1.0	3
145	From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. Cancer Journal (Sudbury, Mass), 2019, 25, 245-253.	1.0	4
146	Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials. Cancer Journal (Sudbury, Mass), 2019, 25, 254-263.	1.0	10
147	Innovation in Oncology Drug Development. Journal of Oncology, 2019, 2019, 1-16.	0.6	10
148	Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D–CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study. JCO Precision Oncology, 2019, 3, 1-10.	1.5	9
149	Basket Designs: Statistical Considerations for Oncology Trials. JCO Precision Oncology, 2019, 3, 1-9.	1.5	11
150	Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. JCO Precision Oncology, 2019, 3, 1-12.	1.5	31
151	Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology. JCO Precision Oncology, 2019, 3, 1-8.	1.5	3
152	Neuroanatomical Quantitative Proteomics Reveals Common Pathogenic Biological Routes between Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). International Journal of Molecular Sciences, 2019, 20, 4.	1.8	74
153	A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma. Neuro-Oncology, 2019, 21, 6-7.	0.6	1
154	Advancing Chronic Obstructive Pulmonary Disease Therapy: Opportunities, Challenges, and Excitement. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 1-2.	1.4	3
155	New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treatment Reviews, 2019, 73, 20-30.	3.4	116

#	ARTICLE	IF	CITATIONS
156	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute, 2019, 111, 118-128.	3.0	49
157	Comment on â€œThe End of Phase 3 Clinical Trials in Biosimilars Development?â€• BioDrugs, 2019, 33, 121-123.	2.2	0
158	Recognizing that Evidence is Made, not Born. Clinical Pharmacology and Therapeutics, 2019, 105, 844-856.	2.3	2
159	E3611â€"A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-Î±2b in Advanced Melanoma. Clinical Cancer Research, 2019, 25, 524-532.	3.2	8
161	Treatment and dose prioritization in early phase platform trials of targeted cancer therapies. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 475-491.	0.5	1
162	Leaping Together Toward Sustainable, Patientâ€Centered Innovation: The Value of a Multistakeholder Safe Haven for Accelerating System Change. Clinical Pharmacology and Therapeutics, 2019, 105, 798-801.	2.3	7
163	Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices. Journal of the National Cancer Institute, 2020, 112, 229-237.	3.0	15
164	Use of Alternative Designs and Data Sources for Pediatric Trials. Statistics in Biopharmaceutical Research, 2020, 12, 210-223.	0.6	3
165	Current State of Hypertrophic Cardiomyopathy Clinical Trials. Global Heart, 2019, 14, 317.	0.9	14
166	Impact of Clinical Center Variation on Efficiency of Exploratory Umbrella Design. Statistics in Biosciences, 2020, 12, 196-215.	0.6	3
167	The rise of innovative clinical trial designs: whatâ€™s in it for amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 3-4.	1.1	1
168	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis Bâ€"Report From the 2019 EASLâ€AASLD HBV Treatment Endpoints Conference. Hepatology, 2020, 71, 1070-1092.	3.6	52
169	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimer's and Dementia, 2020, 16, 131-143.	0.4	45
170	Comparison of methods for control allocation in multiple arm studies using response adaptive randomization. Clinical Trials, 2020, 17, 52-60.	0.7	33
171	The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. Cell, 2020, 180, 9-14.	13.5	45
172	Borrowing strength and borrowing index for Bayesian hierarchical models. Computational Statistics and Data Analysis, 2020, 144, 106901.	0.7	7
173	Genomics and the History of Precision Oncology. Surgical Oncology Clinics of North America, 2020, 29, 35-49.	0.6	23
174	The need for novel trial designs, master protocols, and research consortia in transplantation. Clinical Transplantation, 2020, 34, e13759.	0.8	11

#	ARTICLE	IF	CITATIONS
175	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conferenceâ€¡. Journal of Hepatology, 2020, 72, 539-557.	1.8	208
176	Regulatory Aspects of Genomic Medicine and Pharmacogenomics. , 2020, , 345-360.		1
177	On Optimal Designs for Clinical Trials: An Updated Review. Journal of Statistical Theory and Practice, 2020, 14, 1.	0.3	10
179	Improving natural product research translation: From source to clinical trial. FASEB Journal, 2020, 34, 41-65.	0.2	45
180	Precision Medicine 2030. Clinical Pharmacology and Therapeutics, 2020, 107, 62-64.	2.3	6
181	Development of a Prospective Realâ€World Data Clinical Registry of Children and Adolescents With Migraine. Headache, 2020, 60, 405-415.	1.8	11
182	Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1193-1208.	2.5	137
183	Mastering the Complex Targeted Therapy for Non-small Cell Lung Cancer. Cancer Cell, 2020, 38, 320-322.	7.7	5
184	Integrating trials into a whole-population cohort of children and parents: statement of intent (trials) for the Generation Victoria (GenV) cohort. BMC Medical Research Methodology, 2020, 20, 238.	1.4	11
185	FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development. Orphanet Journal of Rare Diseases, 2020, 15, 234.	1.2	10
186	Advancing combination therapy for Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12073.	1.8	21
188	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism and Related Disorders, 2020, 79, 121-126.	1.1	11
189	Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. Gastroenterology, 2020, 159, 2013-2018.e7.	0.6	16
190	Access to Affordable Orphan Medicines in Europe: An EHA Position Paper. HemaSphere, 2020, 4, e477.	1.2	5
191	Multiplicity issues for platform trials with a shared control arm. Journal of Biopharmaceutical Statistics, 2020, 30, 1077-1090.	0.4	12
192	Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature Communications, 2020, 11, 4965.	5.8	172
193	Tumor organoids to study gastroesophageal cancer: a primer. Journal of Molecular Cell Biology, 2020, 12, 593-606.	1.5	7
194	Basket trials: From tumour gnostic to tumour agnostic drug development. Cancer Treatment Reviews, 2020, 90, 102082.	3.4	15

#	Article	IF	Citations
195	TRICALS: creating a highway toward a cure. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 496-501.	1.1	20
196	COVID-19 Clinical Trials: A Teachable Moment for Improving Our Research Infrastructure and Relevance. Annals of Internal Medicine, 2020, 173, 652-653.	2.0	20
197	A Bayesian basket trial design accounting for uncertainties of homogeneity and heterogeneity of treatment effect among subpopulations. Pharmaceutical Statistics, 2020, 19, 975-1000.	0.7	7
198	Emerging drugs for treatment of focal segmental glomerulosclerosis. Expert Opinion on Emerging Drugs, 2020, 25, 367-375.	1.0	9
199	FIRST-line support for assistance in breathing in children (FIRST-ABC): a master protocol of two randomised trials to evaluate the non-inferiority of high-flow nasal cannula (HFNC) versus continuous positive airway pressure (CPAP) for non-invasive respiratory support in paediatric critical care. BMJ Open, 2020, 10, e038002.	0.8	9
200	Statistical adaptation to oncology drug development evolution. Contemporary Clinical Trials, 2020, 99, 106180.	0.8	1
201	Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. Pain, 2020, 161, 2446-2461.	2.0	64
202	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq1 1 0.784314 rgBT /Overlo	5.1	68
203	Innovative trial design in precision oncology. Seminars in Cancer Biology, 2022, 84, 284-292.	4.3	12
204	Disease trajectory browser for exploring temporal, population-wide disease progression patterns in 7.2 million Danish patients. Nature Communications, 2020, 11, 4952.	5.8	70
205	Strategies to Promote ResiliencY (SPRY): a randomised embedded multifactorial adaptive platform (REMAP) clinical trial protocol to study interventions to improve recovery after surgery in high-risk patients. BMJ Open, 2020, 10, e037690.	0.8	13
206	Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009. BMC Medicine, 2020, 18, 265.	2.3	15
207	Quantitative Methods in Pharmaceutical Research and Development. , 2020, , .		4
208	The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations. Journal of Biopharmaceutical Statistics, 2020, 30, 1026-1037.	0.4	11
209	Contribution of Predictive and Prognostic Biomarkers to Clinical Research on Chronic Kidney Disease. International Journal of Molecular Sciences, 2020, 21, 5846.	1.8	29
210	John D. Loeser Award Lecture: Size does matter, but it isn't everything: the challenge of modest treatment effects in chronic pain clinical trials. Pain, 2020, 161, S3-S13.	2.0	18
212	Effect size estimates from umbrella designs: Handling patients with a positive test result for multiple biomarkers using random or pragmatic subtrial allocation. PLoS ONE, 2020, 15, e0237441.	1.1	2
213	Precision Nephrology Is a Non-Negligible State of Mind in Clinical Research: Remember the Past to Face the Future. Nephron, 2020, 144, 463-478.	0.9	16

#	Article	IF	Citations
214	Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-10.	0.8	5
215	Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials. Cell Systems, 2020, 11, 449-460.e2.	2.9	6
216	The Role of FDA CDER Statisticians in Response Efforts to the COVID-19 Pandemic. Statistics in Biopharmaceutical Research, 2022, 14, 3-4.	0.6	1
217	Clinical impact of a cancer genomic profiling test using an inâ€house comprehensive targeted sequencing system. Cancer Science, 2020, 111, 3926-3937.	1.7	20
218	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. Respiration, 2020, 99, 903-929.	1.2	18
219	Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?. Best Practice and Research in Clinical Haematology, 2020, 33, 101222.	0.7	9
220	Study Designs in Multi-arm Trials for Breast Cancer: A Systematic Literature Review of Major Journals. Therapeutic Innovation and Regulatory Science, 2020, 54, 1185-1191.	0.8	0
221	An overview of platform trials with a checklist for clinical readers. Journal of Clinical Epidemiology, 2020, 125, 1-8.	2.4	72
222	Potential Statistical Issues Between Designers and Regulators in Confirmatory Basket, Umbrella, and Platform Trials. Clinical Pharmacology and Therapeutics, 2020, 108, 444-446.	2.3	11
223	A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates. Frontiers in Pharmacology, 2020, 11, 587.	1.6	26
224	Borrowing of information across patient subgroups in a basket trial based on distributional discrepancy. Biostatistics, 2022, 23, 120-135.	0.9	24
225	Gender differences in molecularâ€guided therapy recommendations for metastatic malignant mesothelioma. Thoracic Cancer, 2020, 11, 1979-1988.	0.8	3
226	Histology-agnostic drug development â€" considering issues beyond the tissue. Nature Reviews Clinical Oncology, 2020, 17, 555-568.	12.5	60
227	Singleâ€Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations Between 2010 and 2019. Clinical Pharmacology and Therapeutics, 2020, 108, 653-660.	2.3	25
228	Master protocols: New directions in drug discovery. Contemporary Clinical Trials Communications, 2020, 18, 100568.	0.5	21
229	Advocacy and Patient Involvement in Clinical Trials. , 2020, , 1-13.		2
230	Generating comparative evidence on new drugs and devices after approval. Lancet, The, 2020, 395, 998-1010.	6.3	52
231	Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints. Statistical Methods in Medical Research, 2020, 29, 2717-2732.	0.7	24

#	ARTICLE	IF	CITATIONS
232	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. New England Journal of Medicine, 2020, 382, 1366-1369.	13.9	63
233	Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomasâ€"Retrospective Analysis of Three Real-Life Clinical Casesâ€"Addressing Issues on Randomization and Customization at the Bedside. Frontiers in Oncology, 2019, 9, 1531.	1.3	3
234	8. Klinische Studien â€" zwischen GCP, CRO und BehÃ¶rden. , 2020, , 257-272.		0
235	Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness. Frontiers in Medicine, 2020, 7, 367.	1.2	8
236	Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting. Clinical Cancer Research, 2020, 26, 4743-4747.	3.2	0
237	The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision. European Respiratory Journal, 2020, 56, 2000627.	3.1	10
238	The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clinical Therapeutics, 2020, 42, 1330-1360.	1.1	74
239	Including non-concurrent control patients in the analysis of platform trials: is it worth it?. BMC Medical Research Methodology, 2020, 20, 165.	1.4	26
240	Randomized Controlled Trials. Chest, 2020, 158, S79-S87.	0.4	48
241	Clinical trials for the prevention and treatment of <scp>COVID</scp> â€19: current state of play. Medical Journal of Australia, 2020, 213, 86-93.	0.8	32
242	Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK. Journal of Crohn's and Colitis, 2020, 14, 1769-1776.	0.6	13
243	An overview of precision oncology basket and umbrella trials for clinicians. Ca-A Cancer Journal for Clinicians, 2020, 70, 125-137.	157.7	116
244	RoBoT: a robust Bayesian hypothesis testing method for basket trials. Biostatistics, 2021, 22, 897-912.	0.9	19
245	Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R. Biometrical Journal, 2020, 62, 1264-1283.	0.6	21
246	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	0.6	1,840
247	Precision Medicine in Soft Tissue Sarcoma Treatment. Cancers, 2020, 12, 221.	1.7	20
248	Genomic profiling in oncology clinical practice. Clinical and Translational Oncology, 2020, 22, 1430-1439.	1.2	4
249	Effective delivery of Complex Innovative Design (CID) cancer trialsâ€"A consensus statement. British Journal of Cancer, 2020, 122, 473-482.	2.9	26

#	ARTICLE	IF	CITATIONS
250	Biased by design? Clinical trials and patient benefit in oncology. Future Oncology, 2020, 16, 4419-4423.	1.1	3
251	Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials. Clinical Pharmacology and Therapeutics, 2020, 107, 1059-1067.	2.3	61
252	Comparison of response adaptive randomization features in multiarm clinical trials with control. Pharmaceutical Statistics, 2020, 19, 602-612.	0.7	16
253	Snapshot: Trial Types in Precision Medicine. Cell, 2020, 181, 208-208.e1.	13.5	13
254	Direct-acting antivirals and viral RNA targeting for hepatitis B cure. Current Opinion in HIV and AIDS, 2020, 15, 165-172.	1.5	3
255	Covid-19 treatment update: follow the scientific evidence. Journal of Thrombosis and Thrombolysis, 2020, 50, 43-53.	1.0	45
256	OPTIM-ARTS—An Adaptive Phase II Open Platform Trial Design With Application to a Metastatic Melanoma Study. Statistics in Biopharmaceutical Research, 2020, , 1-12.	0.6	5
257	Circulating Tumor Cells in Breast Cancer Metastatic Disease. Advances in Experimental Medicine and Biology, 2020, , .	0.8	2
258	A dose-finding approach for genomic patterns in phase I trials. Journal of Biopharmaceutical Statistics, 2020, 30, 834-853.	0.4	0
259	The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired) Tj ETQq1 1 0.784314 rgBT /Overloc	1.5	245
260	Targeted Therapies in Trial for Non-Resectable Gallbladder Cancer. Journal of Gastrointestinal Cancer, 2021, 52, 515-522.	0.6	3
261	The RECOVERY Platform. New England Journal of Medicine, 2021, 384, 757-758.	13.9	47
262	A survey of the feasibility of developing osteoporosis clinical trials in Duchenne muscular dystrophy: Survey of the opinion of young people with Duchenne muscular dystrophy, families and clinicians. Clinical Trials, 2021, 18, 39-50.	0.7	0
263	Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opinion on Drug Discovery, 2021, 16, 125-134.	2.5	3
264	Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis. Clinical Pharmacology and Therapeutics, 2021, 109, 1265-1273.	2.3	21
265	Unifying Themes in Urothelial Cancers. European Urology, 2021, 79, 80-81.	0.9	1
266	Statistical design considerations for trials that study multiple indications. Statistical Methods in Medical Research, 2021, 30, 785-798.	0.7	9
267	Optimizing clinical research procedures in public health emergencies. Medicinal Research Reviews, 2021, 41, 725-738.	5.0	5

#	ARTICLE	IF	CITATIONS
268	Innovative trial designs and analyses for vaccine clinical development. Contemporary Clinical Trials, 2021, 100, 106225.	0.8	18
269	Challenges of drug development during the COVID‑19 pandemic: Key considerations for clinical trial designs. British Journal of Clinical Pharmacology, 2021, 87, 2170-2185.	1.1	15
270	Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials. Statistics in Biopharmaceutical Research, 2021, 13, 248-258.	0.6	6
271	Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine. Statistics in Biopharmaceutical Research, 2021, 13, 133-146.	0.6	3
272	Translational science biostatistics. , 2021, , 359-372.		0
273	A Novel Mixed-Methods Platform Study Protocol for Investigating New Surgical Devices, with Embedded Shared Learning: Ibra-net Breast Lesion Localisation Study. International Journal of Surgery Protocols, 2021, 25, 26-33.	0.5	5
274	A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia. Trials, 2021, 22, 38.	0.7	7
275	Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-7.	1.5	12
276	The changing perspective of clinical trial designs. Perspectives in Clinical Research, 2021, 12, 66.	0.5	6
277	Personalized Medicine for OSA Syndrome in a Nutshell. Chest, 2021, 159, 451-452.	0.4	3
278	The RADx Tech Clinical Studies Core: A Model for Academic Based Clinical Studies. IEEE Open Journal of Engineering in Medicine and Biology, 2021, 2, 152-157.	1.7	12
279	Exploring Heterogeneity in Histology-Independent Technologies and the Implications for Cost-Effectiveness. Medical Decision Making, 2021, 41, 165-178.	1.2	8
280	A master protocol to investigate a novel therapy acetyl-l-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia. Trials, 2021, 22, 84.	0.7	22
281	Hybrid design evaluating new biomarkers when there is an existing screening test. Statistics in Medicine, 2021, 40, 2037-2054.	0.8	0
282	Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics. Statistics in Biopharmaceutical Research, 0, , 1-17.	0.6	5
283	X-change symposium: status and future of modern radiation oncology—from technology to biology. Radiation Oncology, 2021, 16, 27.	1.2	1
284	General medical publications during COVID-19 show increased dissemination despite lower validation. PLoS ONE, 2021, 16, e0246427.	1.1	9
285	Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). Statistics in Medicine, 2021, 40, 2893-2921.	0.8	4

#	ARTICLE	IF	CITATIONS
286	Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. Trials, 2021, 22, 203.	0.7	15
287	Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet, The, 2021, 397, 1063-1074.	6.3	220
288	Systematic review of available software for multi-arm multi-stage and platform clinical trial design. Trials, 2021, 22, 183.	0.7	18
289	Novel Study Designs in Precision Medicine â€" Basket, Umbrella and Platform Trials. Current Reviews in Clinical and Experimental Pharmacology, 2022, 17, 114-121.	0.4	6
290	Clinical Design and Analysis Strategies for the Development of Gene Therapies: Considerations for Quantitative Drug Development in the Age of Genetic Medicine. Clinical Pharmacology and Therapeutics, 2021, 110, 1207-1215.	2.3	4
291	Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods. Pharmaceutical Statistics, 2021, 20, 990-1001.	0.7	2
292	Optimizing subgroup selection in twoâ€stage adaptive enrichment and umbrella designs. Statistics in Medicine, 2021, 40, 2939-2956.	0.8	11
293	Clinical trial preparations for the next pandemic. Contemporary Clinical Trials, 2021, 102, 106292.	0.8	1
294	The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma. Cancers, 2021, 13, 1235.	1.7	16
295	Facing new challenges to informed consent processes in the context of translational research: the case in CARPEM consortium. BMC Medical Ethics, 2021, 22, 21.	1.0	7
296	Value-Generating Exploratory Trials in Neurodegenerative Dementias. Neurology, 2021, 96, 944-954.	1.5	14
297	Clinical cancer genomic profiling. Nature Reviews Genetics, 2021, 22, 483-501.	7.7	79
298	Implementation of Precision Oncology for Patients with Metastatic Breast Cancer in an Interdisciplinary MTB Setting. Diagnostics, 2021, 11, 733.	1.3	13
299	NHLBI-CMREF Workshop Report on Pulmonary Vascular DiseaseÂClassification. Journal of the American College of Cardiology, 2021, 77, 2040-2052.	1.2	13
300	Landscape of interventional clinical trials involving gastrectomy for gastric cancer. Ecancermedicalscience, 2021, 15, 1218.	0.6	2
301	Industrializing engineered autologous T cells as medicines for solid tumours. Nature Reviews Drug Discovery, 2021, 20, 476-488.	21.5	12
302	Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19. JAMA Network Open, 2021, 4, e216468.	2.8	111
303	A systematic review of the evidence supporting post-operative medication use in congenital heart disease. Cardiology in the Young, 2021, 31, 707-733.	0.4	2

#	ARTICLE	IF	CITATIONS
304	Cancer Clinical Trials: What Every Radiologist Wants to Know but Is Afraid to Ask. American Journal of Roentgenology, 2021, 216, 1099-1111.	1.0	3
305	Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors. JTO Clinical and Research Reports, 2021, 2, 100149.	0.6	3
307	Vaccines After an Emergency Use Authorization (EUA): Modern Evidence Generation Approaches. Therapeutic Innovation and Regulatory Science, 2021, 55, 866-871.	0.8	1
308	Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology. Expert Review of Precision Medicine and Drug Development, 2021, 6, 271-280.	0.4	0
309	Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion. Statistics in Biopharmaceutical Research, 2022, 14, 349-352.	0.6	7
310	The use of external controls: To what extent can it currently be recommended?. Pharmaceutical Statistics, 2021, 20, 1002-1016.	0.7	33
311	Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial. Therapeutic Innovation and Regulatory Science, 2021, 55, 926-935.	0.8	0
312	Urgently seeking efficiency and sustainability of clinical trials in global health. The Lancet Global Health, 2021, 9, e681-e690.	2.9	19
313	A systematic review of the evidence supporting post-operative diuretic use following cardiopulmonary bypass in children with Congenital Heart Disease. Cardiology in the Young, 2021, 31, 699-706.	0.4	4
314	Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innovation(China), 2021, 2, 100103.	5.2	47
315	How COVID-19 has fundamentally changed clinical research in global health. The Lancet Global Health, 2021, 9, e711-e720.	2.9	122
316	Current Approaches to Desensitization in Solid Organ Transplantation. Frontiers in Immunology, 2021, 12, 686271.	2.2	14
317	Categories, components, and techniques in a modular construction of basket trials for application and further research. Biometrical Journal, 2021, 63, 1159-1184.	0.6	8
318	Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research. Trials, 2021, 22, 322.	0.7	10
319	Randomised trials at the level of the individual. The Lancet Global Health, 2021, 9, e691-e700.	2.9	11
320	The Landmark Series: Preoperative Therapy for Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 4104-4129.	0.7	17
321	Moving Beyond 3+3: The Future of Clinical Trial Design. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e133-e144.	1.8	33
322	Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. Therapeutic Innovation and Regulatory Science, 2021, 55, 1145-1154.	0.8	31

#	Article	IF	Citations
323	What can heart failure trialists learn from oncology trialists?. European Heart Journal, 2021, 42, 2373-2383.	1.0	9
324	Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk. BMJ Open, 2021, 11, e046799.	0.8	16
325	Artificial intelligence in early drug discovery enabling precision medicine. Expert Opinion on Drug Discovery, 2021, 16, 991-1007.	2.5	35
326	Opportunity for efficiency in clinical development: An overview of adaptive clinical trial designs and innovative machine learning tools, with examples from the cardiovascular field. Contemporary Clinical Trials, 2021, 105, 106397.	0.8	7
327	Planning for the Next Pandemic: Ethics and Innovation Today for Improved Clinical Trials Tomorrow. Statistics in Biopharmaceutical Research, 2022, 14, 22-27.	0.6	4
328	Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design. Future Oncology, 2021, 17, 1987-2003.	1.1	23
329	Guidelines for clinical evaluation of anti€cancer drugs. Cancer Science, 2021, 112, 2563-2577.	1.7	17
330	Sodium-Glucose Co-transporter-2 Inhibitors and Nephroprotection in Diabetic Patients: More Than a Challenge. Frontiers in Medicine, 2021, 8, 654557.	1.2	15
331	Developing Precision Medicine for Bladder Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 633-653.	0.9	9
332	Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers. International Journal of Biostatistics, 2021, .	0.4	0
333	Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expertÂadvice group. Pediatric Research, 2022, 91, 1069-1077.	1.1	8
334	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer€™s disease. Nature Medicine, 2021, 27, 1187-1196.	15.2	182
335	Advancing precision medicine for acute respiratory distress syndrome. Lancet Respiratory Medicine,the, 2022, 10, 107-120.	5.2	83
336	Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion. Statistics in Biopharmaceutical Research, 2022, 14, 353-357.	0.6	15
337	What do we do with our under-enrolled single-center COVID-19 clinical trials?. Clinical Trials, 2021, 18, 174077452110272.	0.7	1
338	Metabolism€based therapies for epilepsy: new directions for future cures. Annals of Clinical and Translational Neurology, 2021, 8, 1730-1737.	1.7	6
339	A new basket trial design based on clustering of homogeneous subpopulations. Journal of Biopharmaceutical Statistics, 2021, 31, 425-447.	0.4	5
340	Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potential. BMC Rheumatology, 2021, 5, 21.	0.6	8

#	Article	IF	Citations
341	Moving forward in clinical research with master protocols. Contemporary Clinical Trials, 2021, 106, 106438.	0.8	4
342	BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells. Anti-Cancer Drugs, 2021, 32, 1076-1083.	0.7	2
343	Making trials part of good clinical care: lessons from the RECOVERY trial. Future Healthcare Journal, 2021, 8, e243-e250.	0.6	32
344	Methodological Issues in Randomized Clinical Trials for Prodromal Alzheimer's and Parkinson's Disease. Frontiers in Neurology, 2021, 12, 694329.	1.1	8
345	Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplantation and Cellular Therapy, 2021, 27, 885-907.	0.6	12
346	A survival mediation model with Bayesian model averaging. Statistical Methods in Medical Research, 2021, 30, 2413-2427.	0.7	4
347	The recurring features of molecular subtypes in distinct gastrointestinal malignancies—A systematic review. Critical Reviews in Oncology/Hematology, 2021, 164, 103428.	2.0	6
348	Causal analyses of existing databases: no power calculations required. Journal of Clinical Epidemiology, 2022, 144, 203-205.	2.4	62
349	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplantation and Cellular Therapy, 2021, 27, 632-641.	0.6	21
351	Pharmacometrics meets statistics—A synergy for modern drug development. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1134-1149.	1.3	9
352	Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis. ESMO Open, 2021, 6, 100187.	2.0	2
354	Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet, The, 2021, 398, 843-855.	6.3	204
355	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplantation and Cellular Therapy, 2021, 27, 729-737.	0.6	29
356	Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet Respiratory Medicine,the, 2021, 9, 1010-1020.	5.2	54
357	Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of Candidate COVID-19 Therapeutics. Annals of Internal Medicine, 2021, 174, 1293-1300.	2.0	26
358	Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies. Neurotherapeutics, 2021, 18, 1445-1457.	2.1	3
359	MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 321-328.	1.1	4
361	Master Protocols and Adaptive Trial Designs to Develop Tumor-Agnostic Drugs for Children. JAMA Oncology, 2021, 7, 1281.	3.4	4

#	ARTICLE	IF	CITATIONS
362	Adaptive Trials in Cardiology: Some Considerations and Examples. Canadian Journal of Cardiology, 2021, 37, 1428-1437.	0.8	2
363	Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 2022, 18, 988-1007.	0.4	42
364	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clinical Cancer Research, 2022, 28, 585-593.	3.2	18
365	A Sequential Predictive Power Design for a COVID Vaccine Trial. Statistics in Biopharmaceutical Research, 0, , 1-25.	0.6	2
366	The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study design of a multi-center pragmatic platform trial. Contemporary Clinical Trials, 2021, 108, 106509.	0.8	5
367	Seeking progress in disease modification in Parkinson disease. Parkinsonism and Related Disorders, 2021, 90, 134-141.	1.1	9
368	Prognostic and predictive biomarker developments in multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 151.	6.9	49
369	Statistical considerations of phase 3 umbrella trials allowing adding one treatment arm mid-trial. Contemporary Clinical Trials, 2021, 109, 106538.	0.8	7
370	Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. Journal of Experimental and Clinical Cancer Research, 2021, 40, 311.	3.5	26
371	An update on drug development for the treatment of metabolic (dysfunction) associated fatty liver disease: Progress and opportunities. Current Opinion in Pharmacology, 2021, 60, 170-176.	1.7	10
372	Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. , 2021, 228, 107932.		44
373	Advances in Targeted Treatments for NSCLC (Excluding EGFR/ALK/ROS-1/K-Ras). , 2022, , 889-904.		0
374	Bridging across patient subgroups in phase I oncology trials that incorporate animal data. Statistical Methods in Medical Research, 2021, 30, 1057-1071.	0.7	2
375	Facing the urgency of therapies for progressive MS â€" a Progressive MS Alliance proposal. Nature Reviews Neurology, 2021, 17, 185-192.	4.9	18
377	How to Achieve a Good Phage Therapy Clinical Trial?. , 2019, , 147-168.		4
378	Challenges for the Optimization of Drug Therapy in the Treatment of Cancer. Computational Biology, 2020, , 163-198.	0.1	2
379	An umbrella approach to test lung cancer therapies. Nature, 2020, 583, 688-689.	13.7	3
380	Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease. Expert Opinion on Investigational Drugs, 2021, 30, 253-262.	1.9	10

#	Article	IF	Citations
383	Highly Efficient Clinical Trials Simulator (HECT): Software application for planning and simulating platform adaptive trials. Gates Open Research, 2019, 3, 780.	2.0	8
384	A paradigm shift in biomarker guided oncology drug development. Annals of Translational Medicine, 2019, 7, 148-148.	0.7	25
385	The Range and Scientific Value of Randomized Trials. Deutsches A&#x0308;rzteblatt International, 2017, 114, 635-640.	0.6	17
386	Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies. Ecancermedicalscience, 2019, 13, 936.	0.6	3
387	The Revolution in Pediatric Drug Development and Drug Use: Therapeutic Orphans No More. Journal of Pediatric Pharmacology and Therapeutics, 2020, 25, 565-573.	0.3	19
388	Complex Innovative Design for Liver Disease Clinical Trials. , 2021, 07, .		0
389	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Preâ€"Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	2.5	72
391	Chinese Herbal Formula Huoxiang Zhengqi for Dampness Pattern in Atopic Dermatitis and Diarrhea-Predominant Irritable Bowel Syndrome: Rationale and Design of a Master Protocol. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-10.	0.5	2
392	Constrained hierarchical Bayesian model for latent subgroups in basket trials with two classifiers. Statistics in Medicine, 2022, 41, 298-309.	0.8	5
393	Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science. Journal of Clinical and Translational Hepatology, 2022, 10, 374-382.	0.7	8
395	Human Subjects Research in Bioemergencies. , 2018, , 183-194.		1
397	An Executiveâ€™s View of Value of Platform Trials. , 2018, , 289-294.		0
398	Clinical Application of Molecular Features in Therapeutic Selection and Drug Development. , 2019, , 137-166.		1
399	Cancer Clinical Trials Based on Master Protocol. Japanese Journal of Biometrics, 2019, 39, 85-101.	0.0	1
400	Understanding Clinical Trials in Malignant Mesothelioma. , 2019, , 187-202.		0
401	Opportunities and challenges of implementing Pharmacogenomics in cancer drug development. , 2019, 2, 43-52.		4
402	Review of Phase II Basket Trials for Precision Medicine. Annals of Biostatistics & Biometric Applications, 2019, 2, .	0.2	1
403	Fundamental concepts for causal inference in medicine. Japanese Journal of Biometrics, 2019, 40, 35-62.	0.0	1

#	Article	IF	Citations
404	Registro de medicamentos com indicaÃ§Ã£o agnÃ³stica jÃ¡ Ã© realidade no Brasil, o que significa para a judicializaÃ§Ã£o?. Cadernos Ibero-americanos De Direito SanitÃ¡rio, 2019, 8, 145-155.	0.1	1
405	Bayesian adaptive design for concurrent trials involving biologically related diseases. Biostatistics, 2022, 23, 1007-1022.	0.9	2
406	Current Status and Future Prospects of Biomarker Strategy for Drug Development. Japanese Journal of Clinical Pharmacology and Therapeutics, 2020, 51, 151-160.	0.1	0
408	Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. The Lancet Global Health, 2022, 10, e42-e51.	2.9	296
409	Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development. Clinical and Translational Science, 2021, 14, 712-719.	1.5	2
410	Biomarkers in drug development. , 2022, , 323-342.		3
411	Integrated Life Cycle Management for Rare and Orphan Products. , 2021, , 351-369.		0
412	Patient Benefits from Innovative Designs in Rare Diseases. , 2021, , 147-160.		2
413	Clinical Relevance and Therapeutic Application of CTCs in Advanced Breast Cancer. Advances in Experimental Medicine and Biology, 2020, 1220, 147-164.	0.8	1
414	Biostatistics in Clinical Trials. , 2020, , 1-70.		0
415	Pragmatic Trials and Approaches to Transforming Care. Success in Academic Surgery, 2020, , 59-76.	0.1	1
417	A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data. Npj Vaccines, 2021, 6, 133.	2.9	2
418	Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group. Clinical Microbiology and Infection, 2022, 28, 1-5.	2.8	15
420	Efficacy Evaluation in the Era of Precision Medicine: The Scope for AI. , 0, , .		0
421	Inferential Frameworks for Clinical Trials. , 2021, , 1-30.		0
422	Clinical care and therapeutic trials in PLS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 67-73.	1.1	6
423	Master protocol trial design for technical feasibility of MR-guided radiotherapy. Radiotherapy and Oncology, 2022, 166, 33-36.	0.3	1
424	Implementation of platform trials in the COVID-19 pandemic: A rapid review. Contemporary Clinical Trials, 2022, 112, 106625.	0.8	26

#	Article	IF	Citations
425	Of some innovations in clinical trial design in hematology and oncology. Therapie, 2021, , .	0.6	0
426	Master Protocols for Precision Medicine in Oncology: Overcoming Methodology of Randomized Clinical Trials. Life, 2021, 11, 1253.	1.1	6
428	A Comparison of Different Approaches to Bayesian Hierarchical Models in a Basket Trial to Evaluate the Benefits of Increasing Complexity. Statistics in Biopharmaceutical Research, 2022, 14, 324-333.	0.6	3
429	The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. Journal of Allergy and Clinical Immunology, 2022, 149, 488-516.e9.	1.5	24
430	Current landscape of clinical development and approval of advanced therapies. Molecular Therapy - Methods and Clinical Development, 2021, 23, 606-618.	1.8	21
433	Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review. AAPS Journal, 2022, 24, 19.	2.2	65
434	Lasciate ogni speranza voi che non sperimentate: il Recovery collaborative group e il Recovery fund. Medico E Bambino, 2020, 39, 551-552.	0.1	1
435	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19. JAMA Network Open, 2022, 5, e2147331.	2.8	38
436	How to Use and Interpret the Results of a Platform Trial. JAMA - Journal of the American Medical Association, 2022, 327, 67.	3.8	36
437	Decision rules for identifying combination therapies in open–entry, randomized controlled platform trials. Pharmaceutical Statistics, 2022, 21, 671-690.	0.7	11
438	Daratumumab for treatment–refractory antibody–mediated diseases in neurology. European Journal of Neurology, 2022, 29, 1847-1854.	1.7	28
439	Challenges for Clinical Drug Development in Pulmonary Fibrosis. Frontiers in Pharmacology, 2022, 13, 823085.	1.6	20
440	Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. Annals of Neurology, 2022, 91, 165-175.	2.8	41
442	Regulatory issues and the potential use of Bayesian approaches for early drug approval systems in Japan. Pharmaceutical Statistics, 2022, , .	0.7	2
443	Challenges and potential strategies utilizing external data for efficacy evaluation in small-sized clinical trials. Journal of Biopharmaceutical Statistics, 2022, 32, 21-33.	0.4	3
444	Resilient Clinical Trial Infrastructure in Response to the COVID-19 Pandemic: Lessons Learned from the TOGETHER Randomized Platform Clinical Trial. American Journal of Tropical Medicine and Hygiene, 2022, 106, 389-393.	0.6	1
445	Bayesian basket trial design with false-discovery rate control. Clinical Trials, 2022, , 174077452110736.	0.7	4
446	Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study. Journal of Biopharmaceutical Statistics, 2022, 32, 170-190.	0.4	8

#	Article	IF	Citations
447	Lessons from the COVID-19 pandemic. Therapie, 2021, 77, 3-3.	0.6	1
448	Novel clinical trial design and analytic methods to tackle challenges in therapeutic development in rare diseases. Annals of Translational Medicine, 2021, .	0.7	3
450	Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren. Springer Reference Medizin, 2021, , 1-57.	0.0	0
451	Therapeutic Targets for Alzheimerâ€™s Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report. journal of prevention of Alzheimer's disease, The, 2022, 9, 231-235.	1.5	2
452	Potential Future Drug Development Lag in Japan Based on an Analysis of Multiregional Clinical Trials in the US, Europe, and East Asia. Therapeutic Innovation and Regulatory Science, 2022, 56, 523-529.	0.8	5
453	Future of Clinical Trial Methodology. Anesthesia and Analgesia, 2022, 134, 668-673.	1.1	4
454	What Are Adaptive Platform Clinical Trials and What Role May They Have in Cardiovascular Medicine?. Circulation, 2022, 145, 629-632.	1.6	19
455	Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. British Journal of General Practice, 2022, 72, e446-e455.	0.7	19
456	Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials. BMJ Open, 2022, 12, e055615.	0.8	8
457	Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective. Expert Review of Anti-Infective Therapy, 2022, 20, 963-979.	2.0	5
458	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2022, 40, 1231-1258.	0.8	96
459	Monotonicity conditions for avoiding counterintuitive decisions in basket trials. Biometrical Journal, 0, , .	0.6	1
460	Predicting outcomes of phase III oncology trials with Bayesian mediation modeling of tumor response. Statistics in Medicine, 2022, 41, 751-768.	0.8	3
461	Can Systems Biology Advance Clinical Precision Oncology?. Cancers, 2021, 13, 6312.	1.7	10
462	Efficiency of a randomized confirmatory basket trial design constrained to control the family wise error rate by indication. Statistical Methods in Medical Research, 2022, 31, 1207-1223.	0.7	7
472	Combination Therapy in Alzheimerâ€™s Disease: Is It Time?. Journal of Alzheimer's Disease, 2022, , 1-17.	1.2	4
473	A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies. Journal of Personalized Medicine, 2022, 12, 669.	1.1	1
474	Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. Trials, 2022, 23, 372.	0.7	4

#	Article	IF	Citations
475	A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints. Biometrics, 2023, 79, 1459-1471.	0.8	1
476	Characteristics of Early Phase Clinical Trials for Rare Cancers: Insights From Interviews With Stakeholders. Frontiers in Pharmacology, 2022, 13, 775217.	1.6	1
477	Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles. Orphanet Journal of Rare Diseases, 2022, 17, 186.	1.2	12
478	A Bayesian Model with Application for Adaptive Platform Trials Having Temporal Changes. Biometrics, 2023, 79, 1446-1458.	0.8	5
479	Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non–Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705). Clinical Lung Cancer, 2022, 23, e395-e399.	1.1	4
480	Study designs for clinical trials applied to personalised medicine: a scoping review. BMJ Open, 2022, 12, e052926.	0.8	11
481	Basket Trials: Review of Current Practice and Innovations for Future Trials. Journal of Clinical Oncology, 2022, 40, 3520-3528.	0.8	10
482	Therapeutic trials in difficult to treat steroid sensitive nephrotic syndrome: challenges and future directions. Pediatric Nephrology, 2023, 38, 17-34.	0.9	4
484	Platform Clinical Trials Within Nephrology—Interpreting the Evidence. American Journal of Kidney Diseases, 2022, , .	2.1	1
485	An adaptive platform trial for evaluating treatments in patients with life‐threatening hemorrhage from traumatic injuries: Rationale and proposal. Transfusion, 2022, 62, .	0.8	2
486	Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis. BMJ, The, 0, , e067745.	3.0	1
487	New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 284-308.	1.4	9
488	Response to Systemic Therapies in Ovarian Adult Granulosa Cell Tumors: A Literature Review. Cancers, 2022, 14, 2998.	1.7	11
489	PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints. Journal of Biopharmaceutical Statistics, 2022, 32, 567-581.	0.4	2
490	<scp>EMBRACE</scp>: One Small Story in Lupus—One Giant Challenge in Clinical Trials. ACR Open Rheumatology, 2022, 4, 747-752.	0.9	6
491	An adaptive platform trial for evaluating treatments in patients with life‐threatening hemorrhage from traumatic injuries: Planning and execution. Transfusion, 2022, 62, .	0.8	2
492	Clinical Trials in Hepatopancreatobiliary Surgery: Assessing Trial Characteristics, Early Discontinuation, Result Reporting, and Publication. Journal of Gastrointestinal Surgery, 2022, 26, 1628-1636.	0.9	0
493	Gastric cancer and genomics: review of literature. Journal of Gastroenterology, 2022, 57, 505-516.	2.3	19

#	ARTICLE	IF	CITATIONS
494	Advancing innovative clinical trials to efficiently deliver medicines to patients. Nature Reviews Drug Discovery, 2022, 21, 543-544.	21.5	4
495	Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19. Blood Advances, 2022, 6, 4710-4714.	2.5	5
496	Economic Evaluation of Cost and Time Required for a Platform Trial vs Conventional Trials. JAMA Network Open, 2022, 5, e2221140.	2.8	12
497	The cross‑over of statistical thinking and practices: A pandemic catalyst. Pharmaceutical Statistics, 2022, 21, 778-789.	0.7	1
498	Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. BMC Medicine, 2022, 20, .	2.3	4
499	Comparative efficacy trials in inflammatory bowel disease: current and future implications for practice. Current Opinion in Gastroenterology, 2022, 38, 337-346.	1.0	5
500	Bayesian local exchangeability design for phase II basket trials. Statistics in Medicine, 0, , .	0.8	2
501	Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland. Applied Health Economics and Health Policy, 2022, 20, 757-768.	1.0	22
502	Inferential Frameworks for Clinical Trials. , 2022, , 973-1002.		0
503	Multi-arm covariate-adaptive randomization. Science China Mathematics, 2023, 66, 163-190.	0.8	2
504	A systematic review of clinical study evidence for pulmonary vasodilator therapy following surgery with cardiopulmonary bypass in children with CHD. Cardiology in the Young, 2022, 32, 1373-1390.	0.4	0
505	The Randomised Controlled Trial at the Intersection of Research Ethics and Innovation. Pharmaceutical Medicine, 0, , .	1.0	0
506	Perpetual observational studies: new strategies to support efficient implementation of observational studies and randomized trials in infectious diseases. Clinical Microbiology and Infection, 2022, 28, 1528-1532.	2.8	3
507	The Bayesian Time Machine: Accounting for temporal drift in multi-arm platform trials. Clinical Trials, 2022, 19, 490-501.	0.7	20
508	Bayesian sample size determination in basket trials borrowing information between subsets. Biostatistics, 0, , .	0.9	2
509	Statistical Considerations in the Design of Clinical Trials Targeting Prodromal Parkinson Disease. Neurology, 2022, 99, 68-75.	1.5	4
510	Novel Clinical Trial Designs in Neuro-Oncology. Neurotherapeutics, 2022, 19, 1844-1854.	2.1	3
511	On model-based time trend adjustments in platform trials with non-concurrent controls. BMC Medical Research Methodology, 2022, 22, .	1.4	21

#	ARTICLE	IF	CITATIONS
512	Improved efficiency for cross-arm comparisons via platform designs. Biostatistics, 0, , .	0.9	0
513	Cancer: slaying the nine-headed Hydra. Annals of Oncology, 2023, 34, 61-69.	0.6	12
514	Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simonâ€™s two-stage design and Bayesian predictive probability monitoring with information sharing across baskets. PLoS ONE, 2022, 17, e0272367.	1.1	3
515	Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic <i>NTRK</i> gene fusion cancers. Journal of Comparative Effectiveness Research, 2022, 11, 1011-1019.	0.6	3
516	COVID-19 Therapeutics: Improviseâ€"Adaptâ€"Learn. Journal of Clinical Medicine, 2022, 11, 5312.	1.0	0
517	Advocacy and Patient Involvement in Clinical Trials. , 2022, , 569-581.		0
518	Platform Trial Designs. , 2022, , 1455-1485.		0
519	DL 101: Basic introduction to deep learning with its application in biomedical related fields. Statistics in Medicine, 2022, 41, 5365-5378.	0.8	0
520	The Role of Master Protocols in Pediatric Drug Development. Therapeutic Innovation and Regulatory Science, 2022, 56, 895-902.	0.8	7
521	An adaptive biomarker basket design in phase <scp>II</scp> oncology trials. Pharmaceutical Statistics, 2023, 22, 128-142.	0.7	2
522	Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. Diabetes Care, 2022, 45, 2189-2201.	4.3	9
523	Challenges, opportunities, and innovative statistical designs for precision oncology trials. Annals of Translational Medicine, 2022, 10, 1038-1038.	0.7	2
524	Mobilizing the clinical trial ecosystem to drive adoption of master protocols. Clinical Trials, 2022, 19, 690-696.	0.7	2
525	Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombinationâ€"deficient hepatocellular carcinoma. Hepatology, 2023, 78, 452-467.	3.6	3
526	Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units. Trials, 2022, 23, .	0.7	4
527	Pragmatic platform trials to improve the outcome of patients with acute kidney injury. Current Opinion in Critical Care, 2022, 28, 622-629.	1.6	0
528	Computer clinical decision support that automates personalized clinical care: a challenging but needed healthcare delivery strategy. Journal of the American Medical Informatics Association: JAMIA, 2022, 30, 178-194.	2.2	5
529	Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients. Trials, 2022, 23, .	0.7	3

#	ARTICLE	IF	CITATIONS
530	Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons. Journal of Hepatology, 2023, 78, 442-447.	1.8	9
531	Alternative Clinical Trial Designs for Nephrology Research. , 2022, , 461-492.		0
532	How Genome-Wide Analysis Contributes to Personalized Treatment in Cancer, Including Gynecologic Cancer?. Comprehensive Gynecology and Obstetrics, 2022, , 115-132.	0.0	0
533	Innovations in Clinical Development in Rare Diseases of Children and Adults: Small Populations and/or Small Patients. Paediatric Drugs, 2022, 24, 657-669.	1.3	1
534	The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice. Frontiers in Oncology, 0, 12, .	1.3	2
535	Design and analysis of umbrella trials: Where do we stand?. Frontiers in Medicine, 0, 9, .	1.2	2
538	Bayesian Modelling Strategies for Borrowing of Information in Randomised Basket Trials. Journal of the Royal Statistical Society Series C: Applied Statistics, 2022, 71, 2014-2037.	0.5	5
539	Precision medicine: the precision gap in rheumatic disease. Nature Reviews Rheumatology, 2022, 18, 725-733.	3.5	15
540	Commentary on the First-Line Support for Assistance in Breathing in Children Trials on Noninvasive Respiratory Support: Taking a Closer Look. Pediatric Critical Care Medicine, 2022, 23, 1084-1088.	0.2	5
543	Epidemiology of commonly used statistical terms, and analysis of clinical studies. , 2023, , 615-623.e1.		0
544	Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	1
545	Applying concepts from "rapid" and "agile" implementation to advance implementation research. Implementation Science Communications, 2022, 3, .	0.8	6
546	Ethical challenges in clinical studies with adaptive design in oncology. Clinical Ethics, 2023, 18, 148-154.	0.5	0
547	Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations—CONCORDE. JCO Precision Oncology, 2022, , .	1.5	0
548	SNRMPACDC: computational model focused on Siamese network and random matrix projection for anticancer synergistic drug combination prediction. Briefings in Bioinformatics, 2023, 24, .	3.2	18
549	Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review. Advances in Therapy, 2023, 40, 1379-1392.	1.3	3
550	Platform trials for anaesthesia and perioperative medicine: a narrative review. British Journal of Anaesthesia, 2023, 130, 677-686.	1.5	3
551	The key elements and application of a master protocol in the development of the core outcome set. Journal of Evidence-Based Medicine, 2022, 15, 320-327.	0.7	2

#	Article	IF	Citations
552	Update on new treatments for rare ovarian tumours. Current Opinion in Obstetrics and Gynecology, 2023, 35, 27-33.	0.9	2
553	Platform trials as the way forward in infectious diseaseâ€™ clinical research: the case of coronavirus disease 2019. Clinical Microbiology and Infection, 2023, 29, 277-280.	2.8	5
554	Progress, development, and challenges in amyotrophic lateral sclerosis clinical trials. Expert Review of Neurotherapeutics, 2022, 22, 905-913.	1.4	2
555	The population-wise error rate for clinical trials with overlapping populations. Statistical Methods in Medical Research, 2023, 32, 334-352.	0.7	4
556	Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet, The, 2023, 401, 281-293.	6.3	174
557	Clinical trials for accelerating pandemic vaccines. Oxford Review of Economic Policy, 2022, 38, 797-817.	1.0	4
558	Gaps and opportunities in sepsis translational research. EBioMedicine, 2022, 86, 104387.	2.7	6
559	The next generation of evidence-based medicine. Nature Medicine, 2023, 29, 49-58.	15.2	129
560	Maximizing the value of the open label extension phase of randomized clinical trials. Journal of Nephrology, 2023, 36, 1561-1563.	0.9	3
561	Examining Endpoint Concordance in Clinical Trials and Real-World Clinical Practice to Advance Real-World Evidence Utilization. Therapeutic Innovation and Regulatory Science, 0, , .	0.8	0
562	The scientific basis of combination therapy for chronic hepatitis B functional cure. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 238-253.	8.2	26
563	What is precision medicine in oncology?. , 2023, , 1-30.		0
564	Why Therapeutic Trials Fail in Primary Tauopathies. Movement Disorders, 2023, 38, 545-550.	2.2	1
565	Master protocol to assess the long-term safety in kidney transplant recipients who previously received Medeorâ€™s cellular immunotherapy products: the MDR-105-SAE. Trials, 2023, 24, .	0.7	0
566	Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial. Statistical Methods in Medical Research, 2023, 32, 963-977.	0.7	1
567	Predicting onset of disease progression using temporal disease occurrence networks. International Journal of Medical Informatics, 2023, 175, 105068.	1.6	1
568	Methodology and design of platform trials: a meta-epidemiological study. Journal of Clinical Epidemiology, 2023, 157, 1-12.	2.4	4
569	Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial. EClinicalMedicine, 2023, 58, 101889.	3.2	9

#	ARTICLE	IF	CITATIONS
570	An interactive R-Shiny app for quickly visualizing a tidy, long dataset with multiple dimensions with an application in clinical trial simulations for platform trials. SoftwareX, 2023, 22, 101347.	1.2	1
571	Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2023, 193, 30-43.	0.7	4
573	Clinical trial considerations for pediatric cancer drug development. Journal of Biopharmaceutical Statistics, 0, , 1-16.	0.4	1
574	Application of Bayesian approaches in drug development: starting a virtuous cycle. Nature Reviews Drug Discovery, 2023, 22, 235-250.	21.5	12
575	Advancing Precision Medicine for the Diagnosis and Treatment of Acute Respiratory Distress Syndrome. Journal of Clinical Medicine, 2023, 12, 1563.	1.0	4
576	Adaptive clinical trials and master protocols. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 313-323.	1.0	0
577	Designing and Implementing â€œLiving and Breathingâ€•Clinical Trials. Critical Care Clinics, 2023, , .	1.0	1
578	Practical basket design for binary outcomes with control of family-wise error rate. BMC Medical Research Methodology, 2023, 23, .	1.4	0
579	Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary. Journal of Gastrointestinal Cancer, 2023, 54, 1276-1285.	0.6	0
580	Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol. Therapeutic Innovation and Regulatory Science, 2023, 57, 823-838.	0.8	2
581	Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints. PLoS ONE, 2023, 18, e0281674.	1.1	1
582	Replacing RCTs with real world data for regulatory decision making: a self-fulfilling prophecy?. BMJ, The, 0, , e073100.	3.0	12
583	Review article: The need for more efficient and patientâ€oriented drug development pathways in NASHâ€"setting the scene for platform trials. Alimentary Pharmacology and Therapeutics, 2023, 57, 948-961.	1.9	4
584	Clinical trials and epidemiology studies. , 2023, , 13-40.		0
585	Basket Trials and Umbrella Trials. , 2023, , 87-100.		0
586	Case Studies of Platform Trials. , 2023, , 115-126.		0
587	Clinical Trials for Personalized Medicine: Design and Data Analysis. Japanese Journal of Biometrics, 2022, 43, 97-119.	0.0	0
588	Accelerating Vaccine Innovation for Emerging Infectious Diseases via Parallel Discovery. SSRN Electronic Journal, 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
589	BEAT CF pulmonary exacerbations core protocol for evaluating the management of pulmonary exacerbations in people with cystic fibrosis. Trials, 2023, 24, .	0.7	1
590	Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. Lancet Oncology, The, 2023, 24, e161-e171.	5.1	4
591	A confirmatory basket design considering non-inferiority and superiority testing. Journal of Biopharmaceutical Statistics, 2024, 34, 205-221.	0.4	0
592	Borrowing Concurrent Information from Non-Concurrent Control to Enhance Statistical Efficiency in Platform Trials. Current Oncology, 2023, 30, 3964-3973.	0.9	2
593	New insights into adaptive enrichment designs. Statistical Papers, 2023, 64, 1305-1328.	0.7	1
595	The MANTRA study: a new umbrella concept prospectively applied to assess implantable medical devices for heart valve procedures. Journal of Cardiothoracic Surgery, 2023, 18, .	0.4	0
596	Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19. Annals of Internal Medicine, 2023, 176, 667-675.	2.0	14
597	Platform Trials. , 2023, , 201-262.		0
614	Clinical Trial Design Innovations for Precision Medicine in Asthma. Advances in Experimental Medicine and Biology, 2023, , 395-412.	0.8	1
617	The potential of innovative trial design for efficiently evaluating repurposed drugs. Nature Reviews Drug Discovery, 2023, 22, 681-682.	21.5	0
625	Designing acute kidney injury clinical trials. Nature Reviews Nephrology, 2024, 20, 137-146.	4.1	4
629	Inflammation across tissues: can shared cell biology help design smarter trials?. Nature Reviews Rheumatology, 2023, 19, 666-674.	3.5	2